Regulation of healthcare services and use of human tissue
We assisted an international provider of personalised oncology testing services to establish its business in New Zealand, including advising on the regulation of healthcare services and use of human tissue.
Mergers and acquisitions for key biotech organisations
We advised Rangatira on the acquisition of laboratory equipment firm Bio-Strategy; and advised NZSX and ASX listed Genesis Research and Development on conversion of its rights to royalties to an interest in Real Time Genomics.
Capital raising
We advised ZyGEM, a biotech company specialising in DNA extraction and testing, on capital raising, contracts, corporate restructuring matters, and the acquisition of US based MicroLab Diagnostics; advised Lypanosys, a pharmaceutical company specialising in dermatological products on a capital raising from various venture capital sponsors, including iGlobe Treasury Management, Cure Kids Ventures, Ice Angels Investments and NZVIF (Seed Fund); and advised Aquaflow Bionomic, a company pioneering the conversion of naturally occurring algae into biofuel, on various corporate matters including a capital raising.
AgResearch – corporate and clinical research advice
We advised AgResearch, New Zealand’s largest Crown Research Institute, on various matters including the fund formation of BioPacificVentures, a NZ$150m life sciences venture capital fund, the sale of animal vaccine company AgVax Developments, and clinical research regulation.
Corporate advice for organisations creating new technologies
We advised Carbonscape, a company specialising in the conversion of plant matter into various green by-products on various corporate matters; and acted for Endeavour i-Cap on its investment in Veritide which has created an anthrax detection device, and Proacta Therapeutics, a pharmaceutical company specialising in products that target cancer.
Advice for pharmaceutical company on capital raising and technology licensing
We advised Protemix, a pharmaceutical company specialising in the prevention and treatment of cardiovascular disease and diabetes on capital raising matters, third party contracts and technology licensing.